Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases
Academic Article
Overview
MeSH Major
Brachytherapy
Brain Neoplasms
Cesium Radioisotopes
Intraoperative Care
Neurosurgical Procedures
abstract
The use of postresection permanent (131)Cs brachytherapy implants resulted in no local recurrences and no radiation necrosis. This treatment was safe, well tolerated, and convenient for patients, resulting in a short radiation treatment course, high response rate, and minimal toxicity. These findings merit further study with a multicenter trial.